The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model

Documenti analoghi

• Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
  di: Krendyukov A, et al.
  Pubblicazione: (2019-09-01)
• CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
  di: Richards DM, et al.
  Pubblicazione: (2021-03-01)
• Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
  di: Nina Hanke, et al.
  Pubblicazione: (2019-04-01)
• Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context
  di: Maria Pilar Ruiz Seco, et al.
  Pubblicazione: (2024-11-01)
• The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
  di: Charlotte Lemech, et al.
  Pubblicazione: (2012-03-01)